Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study
Name:
37691870.pdf
Size:
131.7Kb
Format:
PDF
Description:
Identified with Open Access button
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2023
Metadata
Show full item recordAbstract
NoneCitation
Gómez-Randulfe I, Califano R. Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study. Translational lung cancer research. 2023 Aug 30;12(8):1812-5. PubMed PMID: 37691870. Pubmed Central PMCID: PMC10483088. Epub 2023/09/11. eng.Journal
Translational Lung Cancer ResearchDOI
10.21037/tlcr-23-290PubMed ID
37691870Additional Links
https://doi.org/10.21037/tlcr-23-290Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.21037/tlcr-23-290
Scopus Count
Collections
Related articles
- Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
- Authors: Nosaki K, Saka H, Hosomi Y, Baas P, de Castro G Jr, Reck M, Wu YL, Brahmer JR, Felip E, Sawada T, Noguchi K, Han SR, Piperdi B, Kush DA, Lopes G
- Issue date: 2019 Sep
- Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data.
- Authors: Jemielita T, Li XN, Piperdi B, Zhou W, Burke T, Chen C
- Issue date: 2021 Jan
- Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
- Authors: Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, Rodríguez-Cid J, Tafreshi A, Cheng Y, Lee KH, Golf A, Sugawara S, Robinson AG, Halmos B, Jensen E, Schwarzenberger P, Pietanza MC, Paz-Ares L
- Issue date: 2023 Apr 10
- Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042.
- Authors: Mansfield AS, Herbst RS, de Castro G Jr, Hui R, Peled N, Kim DW, Novello S, Satouchi M, Wu YL, Garon EB, Reck M, Robinson AG, Samkari A, Piperdi B, Ebiana V, Lin J, Mok TSK
- Issue date: 2021 Aug
- Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.
- Authors: Wu YL, Zhang L, Fan Y, Zhou J, Zhang L, Zhou Q, Li W, Hu C, Chen G, Zhang X, Zhou C, Dang T, Sadowski S, Kush DA, Zhou Y, Li B, Mok T
- Issue date: 2021 May 1